Noxopharm logo

NOX - Noxopharm News Story

A$0.685 -0.0  -2.1%

Last Trade - 1:26am

Sector
Healthcare
Size
Small Cap
Market Cap £97.4m
Enterprise Value £87.4m
Revenue £3.19m
Position in Universe 672nd / 1914

BUZZ-Australia's Noxopharm notches best day in 3 months as co to start drug trial

Fri 7th May, 2021 3:49am
** Shares of Noxopharm Ltd  NOX.AX  rise as much as 19.6% to
A$0.580, their biggest intraday pct gain since Feb 9
    ** The drug developer says CEP-2 study of its drug Veyonda,
used for chemotherapy and radiotherapy, will open shortly
following Investigational New Drug (IND) granted by Food and
Drug Administration (FDA) approval  urn:newsml:reuters.com:*:nGLF7jQJYp
    ** CEP-2 is a Phase I study where approximately 40 patients
with a range of soft tissue sarcomas will receive the
Veyonda/doxorubicin combination 
    ** Says study designed to provide proof-of-principle of
ability of Veyonda to enhance chemotherapy
    ** Says CEP-2 builds on encouraging outcomes of CEP-1 pilot 
study 
    ** More than 1.6 mln shares change hands, vs the 30-day
average volume of ~619,300 shares
    ** Stock down 1% this year, as of last close
    
  

 (Reporting by Vasudha Kaukuntla in Bengaluru)
 ((Vasudha.Kaukuntla@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.